drugset

drugset / Trial / NCT02379910

A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis

NCT02379910 ↗

Phase 1/2 Completed 36 enrolled AnaMar AB Covance · collab

RandomizedSingle-groupQuadruple-blindTreatment

Summary

This is a study of safety, tolerability, pharmacokinetics and pharmacodynamics of AM1030-CREAM in patients with Atopic Dermatitis.

Timeline

Start: 2014-11
Primary completion: 2015-06
Completion: 2015-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AM1030	Unknown	—	Topical

Indications